Company intelligence / Profile preview

Myolex

Brookline, Massachusetts, United Statesmyolex.com ↗

Ownership: Private
Development stage: Commercial

Overview

Myolex’s EIM platform has been validated in over 150 published clinical studies and is supported by 10 issued patents. The mScan device provides a non-invasive, quantitative, portable method to assess muscle health and disease progression. Peer-reviewed research demonstrates its sensitivity in detecting early muscle deterioration in conditions like ALS and DMD. The company is advancing toward FDA clearance with support from NIH grants.

Therapeutic areas: Neurology
Modalities: Device (Electrical Impedance Myography)
Industry: Physiological Monitoring

Partnerships

Multiple pharmaceutical companies supporting >10 clinical studies using EIM technologyNational Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) via SBIR grant funding

Beyond the preview

Go deeper on Myolex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myolex.

Explore the full profile